A61K 38 - Medicinal preparations containing peptides

Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
11/2001
11/29/2001	WO2001089540A1 Use of egg white and egg white fractions for tissue regeneration
11/29/2001	WO2001089531A1 Crystal structures of p- selectin,ep0105895-selectin complexes, and uses thereof
11/29/2001	WO2001089509A2 Method of treating hiv-1 disease
11/29/2001	WO2001089486A1 Nonoral preparation having three-layer structure
11/29/2001	WO2001089481A1 Prolonged release microspheres for injection delivery and preparation method
11/29/2001	WO2001089479A2 Sustained release pharmaceutical compositions for parenteral administration of hydrophilic compounds
11/29/2001	WO2001089457A2 Thrombopoietin mimetics
11/29/2001	WO2001089450A2 Treating musculoskeletal disorders using lp85 and analogs thereof
11/29/2001	WO2001089319A2 Tryptophan source from plants and uses therefor
11/29/2001	WO2001089316A1 Feedstuff additive
11/29/2001	WO2001089303A1 Methods of modulating the activity of mura
11/29/2001	WO2001089298A2 Compositions and methods of nematode control
11/29/2001	WO2001089282A2 2-amino-3-hydroxy-4-tert-leucyl-amino-5-phenyl-pentanoic acid amide derivatives
11/29/2001	WO2001062284A3 Novel method for down-regulation of amyloid
11/29/2001	WO2001058935A3 FACTOR VII OR VIIa-LIKE MOLECULES
11/29/2001	WO2001055173A8 Nucleic acids, proteins, and antibodies
11/29/2001	WO2001053515A8 Methods and materials relating to novel interleukin-1 receptor-like polypeptides and polynucleotides
11/29/2001	WO2001051509A3 Shc-associated protein 140 (sap-140)
11/29/2001	WO2001047954A3 NOVEL cDNAs ENCODING CATENIN-BINDING PROTEINS WITH FUNCTION IN SIGNALLING AND/OR GENE REGULATION
11/29/2001	WO2001044490A3 A NOVEL METHOD TO PRODUCE HUMAN NATURAL INTERFERON-$g(a)
11/29/2001	WO2001044465A3 Therapeutically useful synthetic oligonucleotides
11/29/2001	WO2001044458A3 Bovine immunodeficiency virus (biv) based vectors
11/29/2001	WO2001044272A3 Daptomycin analogs as antibacterial agents
11/29/2001	WO2001043764A3 Methods for treating pervasive development disorders
11/29/2001	WO2001042471A8 Polypeptides and polynucleotides encoding same
11/29/2001	WO2001040451A3 Masp-3, a complement-fixing enzyme, and uses for it
11/29/2001	WO2001040293A3 Method of modulating proapoptotic and antiapoptotic pathways in cells
11/29/2001	WO2001040257A3 Modified il-12 subunits and nucleic acids encoding them
11/29/2001	WO2001039793A3 Pharmaceutical compositions containing sema7a polypeptides
11/29/2001	WO2001038566A3 Screening method for candidate drugs
11/29/2001	WO2001038353A3 Human wnt gene
11/29/2001	WO2001038347A3 Peptides having antiangiogenic activity
11/29/2001	WO2001036644A3 Wnt-regulated cytokine-like polypeptide and nucleic acids encoding same
11/29/2001	WO2001034095A8 A method for treating viral diseases and other disorders by altering immediate gene expression through administration of peptide t
11/29/2001	WO2001031007A3 Nucleic acid molecules derived from rat brain and programmed cell death models
11/29/2001	WO2001029234A3 Self-cleaving rna sequences and their use for the control of protein synthesis
11/29/2001	WO2001028544A3 Dialysis solution including polyglycol osmotic agent
11/29/2001	WO2001027138A3 Modulators of srebp processing
11/29/2001	WO2001025433A3 Novel polypeptides, their nucleic acids, and methods for their use in angiogenesis and vascularization
11/29/2001	WO2001023590A3 22196, a novel human aminopeptidase
11/29/2001	WO2001023560A3 Isolated peptides which bind to mhc class ii molecules, and uses thereof
11/29/2001	WO2000073469A3 Protein kinases
11/29/2001	WO2000064919A9 Compositions, methods, and kits relating to the tig-1 gene, a novel tzd inducible gene
11/29/2001	WO2000050063A9 Combinations and methods for promoting in vivo liver cell proliferation and enhancing in vivo liver-directed gene transduction
11/29/2001	WO2000047104A9 Antagonists of hmg1 for treating inflammatory conditions
11/29/2001	WO2000045792A8 Hydrogel particle formulations
11/29/2001	WO2000043505A3 Protease with two aspartate radicals in the catalytically active structure
11/29/2001	WO2000041548A3 Methods for glucagon suppression
11/29/2001	WO2000040722A3 Insulin-synthesis genes
11/29/2001	WO2000034310A9 Purified and isolated serine-threonine kinase receptors associated protein
11/29/2001	US20010047090 VANILREP1 polynucleotides and VANILREP1 polypeptides
11/29/2001	US20010047085 Adding to the protein solution a cyclodextrin in an amount sufficient to form a stable complex with the protein, lyophilizing, recovering lyophilized protein/cyclodextrin complex, heating complex to inactivate viruses
11/29/2001	US20010047084 Extendin derivatives
11/29/2001	US20010047083 Produced by hybridoma cell line ATCC No. HB12003 and progeny thereof; used in detection or treatment of carcinoembryonic antigen associated tumors
11/29/2001	US20010047082 Soluble keratin peptide
11/29/2001	US20010047080 Inhibits hiv infection of cells
11/29/2001	US20010047079 Caused by rhabdomyolysis or myoglobinuria
11/29/2001	US20010047035 Detecton, treatment and monitoring the patient with poor wound healing ability due to diabetes based on measurement of the breakdown product of nitric oxide (NO) in specimens taken from the patient under controlled conditions
11/29/2001	US20010047030 Somatostatin antagonists and agonists that act at the SST subtype 2 receptor
11/29/2001	US20010046981 N-acyl-heterocycle-carboxyamides that are N-substituted with amidino-substituted rings; competitive inhibitors of thrombin; anticoagulants
11/29/2001	US20010046976 Antimicrobial histone h1 compositions, kits, and methods of use thereof
11/29/2001	US20010046968 Angiogenesis inhibition; especially administering naltrexone, naloxone, antibody against OGF or OGF receptor, or antisense molecule of OGF- receptor-encoding gene
11/29/2001	US20010046966 Gene therapy.
11/29/2001	US20010046965 Making them safer for the large-scale production of adenovirus stock for use in human gene therapy trials.
11/29/2001	US20010046962 Presynaptic neurotoxin such as botulinum toxin A
11/29/2001	US20010046958 Methods of treating diabetic cardiomyopathy using glycogen phosphorylase inhibitors
11/29/2001	US20010046957 Administering interferon-alpha or a pegylated derivative and a salt or prodrug of mycophenolic acid
11/29/2001	US20010046956 May contain another compound to treat diabetes, sexual dysfunction, atherosclerosis, insulin resistance, impaired glucose tolerance, hypercholesterolemia or hypertriglyceridemia
11/29/2001	US20010046955 Administering an agent that increases the biological activity of a calcitonin gene related peptide receptor in the lungs, such as a corticosteroid, beta-agonist, leukotriene inhibitor, antihistamine or phosphodiesterase inhibitor
11/29/2001	US20010046954 Bioavailability enhancing compound which may be non-reducing carbohydrate; amino acid or polymer; hydroxamate; or oxo-acid salt, especially s basic sodium phosphate; suspended in a hydrophobic carrier; increasing milk production
11/29/2001	US20010046680 Identification of polypeptides and nucleic acid molecules using linkage between DNA and polypeptide
11/29/2001	US20010046524 Administering to the patient a formulation comprising an extract of Eucommia ulmoides (plant extract) or an extract of botanical equivalent of Eucommia extract or acomponent to modulalte steroid-mediated physiological condition
11/29/2001	US20010046512 An antibody capable of specifically inhibiting the fusion of an HIV-1 envelope glycoprotein cell with a CD4+ cell without cross reacting with the HIV-1 envelope glycoprotein or CD4 and inhibits infection by strains of HIV-1
11/29/2001	US20010046505 An implantable medical device comprising a polyarylate, polymerized as a random block copolymer of a dicarboxylic acid with both tyrosine-derived diphenol and poly (alkylene oxide) in a specific ratio; used for drug delivery
11/29/2001	US20010046503 Reduction of adhesions using controlled delivery of active oxygen inhibitors
11/29/2001	US20010046499 Tick antigens and compositions and methods comprising them
11/29/2001	US20010046498 Chimeric prostate-homing peptide comprising a sequence of serine-methionine-serine-isoleucine-alanine-arganine-leucine, or functionally equivalent sequence
11/29/2001	US20010046495 Use of cross-linked, covalently bound urokinase plasminogen activator (scuPAR)-urokinase plasminogen activator receptor (suPAR) complex as a fibrinolytic agent
11/29/2001	US20010046494 Feeding an animal a polysaccharidase enzyme selected from xylanase, cellulase and mixture, mixed with an animal feed or drinking water to treat bacterial infection
11/29/2001	US20010046493 Lipase-containing composition and methods of use thereof
11/29/2001	US20010046490 Cell surface molecule-induced macrophage activation
11/29/2001	US20010046489 Stem cells of the islets of langerhans and their use in treating diabetes mellitus
11/29/2001	US20010046486 Stimulation of thymus for vaccination development
11/29/2001	US20010046483 Medicaments for manipulating T-cell immune response
11/29/2001	US20010046482 Enhance motility of the digestive tract and/or contractility of the lower esophageal sphincter
11/29/2001	US20010045465 Bar code scanner with collimated scan volume
11/29/2001	US20010045213 Method of treating diabetes mellitus in a patient
11/29/2001	EP1144603A3 Protease
11/29/2001	DE10025948A1 Wirkstoffkombination Combination of active ingredients
11/29/2001	DE10025045A1 Mittel zur Stimulation des Immunsystems Means for stimulation of the immune system
11/29/2001	DE10024451A1 Pharmazeutische Darreichungsform für Peptide, Verfahren zu deren Herstellung und Verwendung Pharmaceutical form of administration for peptides, process for their preparation and use
11/29/2001	DE10024384A1 Herstellung von dendritischen Zellen aus Rückenmarkstammzellen Preparation of dendritic cells from spinal cord stem cells
11/29/2001	DE10024383A1 Mit toxischen Substanzen beladene dendritische Zellen With toxic substances loaded dendritic cells
11/29/2001	CA2808215A1 Nrg-2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
11/29/2001	CA2429199A1 Drug metabolizing enzymes
11/29/2001	CA2410987A1 Inhibition of smad3 to prevent fibrosis and improve wound healing
11/29/2001	CA2410827A1 Methods and compositions for enhancing the delivery of a nucleic acid toa cell
11/29/2001	CA2410567A1 Formulations and use of activated protein c and protein c zymogen for treating hypercoagulable states
11/29/2001	CA2410563A1 Methods for preventing strokes by inducing tolerance to e-selectin
11/29/2001	CA2410520A1 Mutated eukariotic translation initiation factor 2 alpha kinase 3, eif2ak3, in patients with neonatal insulin-dependent diabetes and multiple epiphyseal dysplasia (wolcott-rallison syndrome)

1 ... 2156 2157 2158 2159 2160 2161 2162 2163 2164 2165 2166 2167 2168 2169 2170 2171 2172 2173 2174 2175 2176 ... 3163